Anthony Doyle, Chief Financial Officer at BIOCRYST PHARMACEUTICALS INC (BCRX), sold 5,700 shares at $10.90 ($62K) on 2022-12-15, disclosed to the SEC on 2022-12-19.
Open-market sale of $62k BCRX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| BCRX | BUY | 2020-08-12 | $220K | — | Filing → |